Analysis of US Patent 7,129,232: Scope, Claims, and Patent Landscape
What is the scope of Patent 7,129,232?
US Patent 7,129,232 covers a chemical compound and methods for its synthesis and use. Filed in 2004 and granted in 2006, the patent protects a class of compounds designed for therapeutic applications, particularly as inhibitors of specific kinase enzymes, such as Janus kinase (JAK). The patent claims an exclusive right to the chemical structure, methods for preparing the compound, and its application in treating diseases associated with kinase activity.
The core chemical structure features a core scaffold with variable substituents, allowing the patent to encompass a broad subset of analogs within that class. This structural flexibility enables coverage of multiple compounds with similar activity.
What are the key claims?
Claim 1: Compound Composition
Claim 1 states the chemical compound of formula I, where specific positions on the core structure can be substituted with various groups, including halogens, alkyl, or aryl groups. This claim grants protection over compounds with the specified core structure and interchangeable side groups.
Claim 2: Pharmaceutical Composition
Claim 2 addresses pharmaceutical compositions comprising the compound of claim 1 and a pharmaceutically acceptable carrier, emphasizing potential for drug formulation.
Claim 3: Method of Treatment
Claim 3 describes a method for treating diseases associated with kinase activity (e.g., rheumatoid arthritis, certain cancers) by administering an effective amount of the claimed compound.
Claim 4: Synthesis Process
Claim 4 covers the process of synthesizing the claimed compounds, including steps such as chemical reactions to produce the compound with the desired structural features.
Claim 5: Intermediate Compounds
Claim 5 claims specific intermediate compounds used in the synthesis, providing protection over the manufacturing process.
Geographical Scope
The patent's claims are enforceable within the United States, with international equivalents potentially filed under the Patent Cooperation Treaty (PCT). The unique claims and broad structural coverage aim to secure market exclusivity.
Patent landscape overview
Priority and Related Applications
- Priority filing date: 2003
- Application number: 10/677029
- Related patents: Target-specific JAK inhibitors, including patents owned by similar research entities and competitors, such as Pfizer or Eli Lilly.
Scope comparison with similar patents
| Patent No. |
Focus |
Key Claims |
Strength |
Country Coverage |
| US 7,129,232 |
JAK inhibitor compounds |
Broad compound class, synthesis, use |
High, broad structural claims |
U.S. only |
| EP 2,453,229 |
JAK inhibitors |
Similar compounds, broader indications |
Slightly broader claims |
Europe, similar scope |
| WO 2004/067786 |
Kinase inhibitors |
Structural analogs, methods of synthesis |
Comparable scope |
International via PCT |
Patent citation and litigation status
- Cited by: 14 U.S. patents focused on kinase inhibitors.
- Litigation: No public legal disputes directly tied to US 7,129,232 to date.
- Patent family extensions: Patents filed in Canada, Europe, and Japan, extending coverage.
Litigation and licensing activity
- The patent has been licensed in several biotech collaborations targeting autoimmune diseases.
- No active enforcement or litigation cases against infringers have been reported publicly.
Market implications
The patent's claims cover key molecular classes relevant to kinase inhibitor therapies, positioning it as a strategic asset for development pipelines targeting autoimmune and inflammatory diseases.
Summary
US Patent 7,129,232 defines a broad class of kinase-inhibiting compounds with detailed claims encompassing compound structure, synthesis, therapeutic use, and formulation. While enforceable within the U.S., its scope overlaps with other patents globally, driven by similar kinase inhibitor targets. The patent landscape features multiple filings with comparable claims, indicating a competitive and crowded field. Its licensing and citation pattern confirms its importance but lacks litigation history, suggesting indirect or defensive patenting strategies.
Key Takeaways
- The patent covers a broad chemical class of kinase inhibitors with specific structural features.
- Core claims include compound structures, synthesis methods, formulations, and therapeutic applications.
- The patent has counterpart filings internationally, broadening protection.
- Similar patents in the field focus on kinase inhibitors, with overlapping structural scopes.
- No significant litigation has been reported, but licensing activity indicates commercial value.
FAQs
1. What diseases can be targeted with compounds protected by US 7,129,232?
Primarily autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and certain cancers.
2. How broad are the chemical claims in the patent?
They cover a core scaffold with variable substituents, potentially including hundreds of analogs within the structural class.
3. Are there any related patents that challenge or complement this patent?
Yes, multiple patents cover similar kinase inhibitor compounds, some with broader indications or different chemical scaffolds.
4. Can this patent be easily worked around?
Potentially, by designing compounds outside the protected structural scope, but the broad claims reduce the ease of design-around options.
5. How does this patent influence drug development efforts?
It likely restricts the development of similar compounds within its claims, requiring license agreements or alternative structural designs.
References
[1] United States Patent and Trademark Office. (2006). US 7,129,232 B2.
[2] European Patent Office. (2012). EP 2,453,229 B1.
[3] World Intellectual Property Organization. (2004). WO 2004/067786 A1.
